Papers

1

Total Citations

13

H-Index

1

About

Christoph Malkmus is a pioneering researcher at the intersection of robotics and tissue engineering, whose work is reshaping the future of drug testing and biomedical research. His primary focus lies in developing automated, animal-free platforms for producing 3D epithelial tissues, a critical advancement in the wake of regulatory shifts away from mandatory animal testing. Malkmus’s landmark 2024 paper, "ReBiA—Robotic Enabled Biological Automation: 3D Epithelial Tissue Production," has already garnered 13 citations, signaling its rapid influence. In this work, he introduces a fully robotic system that streamlines the complex, labor-intensive process of culturing human epithelial tissues, enabling high-throughput, reproducible production. This innovation directly addresses the growing demand for ethical, human-relevant testing models, as highlighted by the FDA’s recent policy changes and the European Parliament’s push for faster adoption of animal-free methods. Malkmus’s contributions are not merely technical; they are deeply aligned with a global movement toward more humane and accurate preclinical research. By automating tissue fabrication, he is lowering barriers for labs to transition away from animal models, making his work both timely and transformative. His achievements position him as a key figure in the next generation of biofabrication, where robotics and biology converge to create safer, more ethical pathways for drug development.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
ReBiA—Robotic Enabled Biological Automation: 3D Epithelial Tissue Production
13 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 15
🏛 Institutions: Technical University of Applied Sciences Würzburg-Schweinfurt

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago